63 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Influence of polar side chains modifications on the dual enkephalinase inhibitory activity and conformation of human opiorphin, a pain perception related peptide.
Institute of Advanced Chemistry of Catalonia (Iqac-Csic)
Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.
Pharmaleads
New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.
Pharmaleads
Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor.
University of Siena
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.
University of Lille
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.
Glaxosmithkline
Dual metalloprotease inhibitors. III. utilization of bicyclic and monocyclic diazepinone based mercaptoacetyls
TBA
Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls
TBA
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
Universite£
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.
Wroclaw University of Technology
Proposed Bioactive Conformations of Opiorphin, an Endogenous Dual APN/NEP Inhibitor.
TBA
Structure-activity relationship study of opiorphin, a human dual ectopeptidase inhibitor with antinociceptive properties.
Institute of Advanced Chemistry of Catalonia (Iqac-Csic)
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
University Institute of Pathology
Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.
Institute of Biomedical Chemistry of Russian Academy of Medical Sciences
Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs.
University of Paris
Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Novartis Pharmaceuticals
Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation.
University of Paris
Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11
TBA
Synthesis and evaluation of 2-(biphenylmethyl)glutaric acid amide derivatives as neutral endopeptidase inhibitors.
TBA
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by N-phosphonomethyl and N-carboxyalkyl dipeptides
TBA
Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors.
Pfizer
Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
Cea
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by tricyclic benzazepinone thiols
TBA
Studies on the structural feature of S'1 subsite of neprilysin (EC.3.4.24.11): Stereochemical requirement for the enzyme-inhibitor docking process
TBA
Non-peptidic inhibitors of neutral endopeptidase 24.11 2. Design and pharmacology of orally active phosphonate prodrugs
TBA
Synthesis of 6-amino-5-oxo-7-phenyl-1,4-oxazepines as conformationally constrained gauche (−) dipeptide mimetics
TBA
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
University of Athens
Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2.
Mount Sinai School of Medicine
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.
Glaxosmithkline
2-Aminothiophene scaffolds: Diverse biological and pharmacological attributes in medicinal chemistry.
Xinjiang Technical Institute of Physics and Chemistry
Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.
Vrije Universiteit Brussel
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder.
Pfizer
A concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years.
University of Electronic Science and Technology of China
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.
Pfizer
Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition.
University of Cape Town
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
University of Nebraska Medical Center
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.
British Biotech Pharmaceuticals
2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.
F. Hoffmann-La Roche
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.
University of Bath
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Novartis Institutes For Biomedical Research
Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.
Ciba-Geigy
Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.
Novartis Pharmaceuticals
A mechanism-based inactivation study of neutral endopeptidase 24.11.
Salk Biotechnology/Industrial Associates
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
University of Paris
Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome.
Ranbaxy Laboratories
